Chromenone Derivatives as CRM1 Inhibitors for Targeting Glioblastoma

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Glioblastoma (GBM) is a highly aggressive brain cancer with limited treatment options due to complex signaling networks.
• Targeted therapies often fail due to pathway redundancy.
• Chromosome Region Maintenance 1 (CRM1) is a nuclear export receptor and a potential therapeutic target for GBM.

Purpose of the Study:

• To investigate chromenone derivatives as novel inhibitors of CRM1.
• To establish structure-activity relationships (SAR) for CRM1 inhibition by chromenones.
• To evaluate the efficacy of chromenone derivatives in glioblastoma cells.

Main Methods:

• Synthesis of novel chromenone derivatives.
• In vitro assays to assess CRM1 inhibition and nuclear export.
• Structure-activity relationship (SAR) analysis.
• Molecular docking studies for binding rationale.
• Cytotoxicity assays in glioblastoma cell lines.

Main Results:

• Chromenone derivatives were synthesized and demonstrated dose- and structure-dependent inhibition of CRM1-mediated nuclear export.
• Preliminary SAR and molecular docking provided insights into selective CRM1 binding.
• Active compounds inhibited the nuclear export of endogenous substrates in glioblastoma cells.
• Several derivatives showed selective cytotoxicity against glioblastoma cell lines.

Conclusions:

• Chromenone derivatives are effective inhibitors of CRM1.
• These compounds represent a potential new class of targeted therapies for glioblastoma.
• Further development of chromenone-based CRM1 inhibitors is warranted for GBM treatment.